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Abstract
Objective To investigate the association between sele-
nium and the risk of Barrett’s esophagus (BE), the pre-
cursor lesion of esophageal adenocarcinoma.
Methods Data from the prospective Netherlands Cohort
Study were used. This cohort study was initiated in 1986,
when 120,852 subjects aged 55–69 years completed a
questionnaire on dietary habits and lifestyle, and provided
toenail clippings for the determination of baseline selenium
status. After 16.3 years of follow-up, 253 BE cases (iden-
tiﬁed through linkage with the nationwide Dutch pathology
registry) and 2,039 subcohort members were available for
case–cohort analysis. Cox proportional hazards models
were used to calculate incidence rate ratios (RR).
Results The multivariable-adjusted RR for the highest
versus the lowest quartile of toenail selenium was 1.06
(95% CI 0.71–1.57). No dose–response trend was seen
(p trend = 0.99). No association was found in subgroups
deﬁned by sex, smoking status, body mass index (BMI), or
intake of antioxidants. For BE cases that later progressed to
high-grade dysplasia or adenocarcinoma, the RR for a
selenium level above the median vs. below the median was
0.64 (95% CI 0.24–1.76).
Conclusions In this large prospective cohort study, we
found no evidence of an association between selenium and
risk of BE.
Keywords Barrett esophagus  Biological markers 
Selenium
Introduction
Barrett’s esophagus (BE) is a disease of the distal esoph-
agus. Normally, the esophagus is lined with stratiﬁed
squamous epithelium, which is replaced by a single layer
of columnar epithelium (metaplasia) in BE patients.
Diagnostic criteria for BE differ across the world. In the
USA, the presence of goblet cells (indicating specialized
intestinal metaplasia, SIM) is required for the diagnosis of
BE [1], while in the United Kingdom, any type of meta-
plasia is sufﬁcient for the diagnosis of BE [2]. In the
Netherlands, both deﬁnitions have been used by different
pathologists over time.
BE is most common in middle-aged Caucasian men [3]
and in the Netherlands, the incidence is rising among men
and women [4]. BE has primarily been of interest because
patients are at increased risk to develop adenocarcinoma
of the esophagus. The reported risk of esophageal
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DOI 10.1007/s10552-010-9651-1adenocarcinoma in BE patients is highly variable between
publications and was found in a recent meta-analysis to
be between 4.1/1,000 and 6.1/1,000 person-years [5].
Patients in whom high-grade dysplasia is present in the
BE tissue are at highest risk of developing esophageal
adenocarcinoma [6].
Gastroesophageal reﬂux disease has been identiﬁed as a
strong risk factor for BE, and possibly overweight or
obesity are risk factors as well [7]. Lifestyle factors,
including diet, may also play a role in BE etiology [7–9],
but little information is available on this topic.
Onedietaryfactor ofinterestisselenium, atrace element,
which has been investigated for its possible role in cancer
etiology. Selenium is involved in various anticarcinogenic
processes and may act at a number of stages in cancer
development [13]. Selenium is incorporated into some se-
lenoproteins including glutathione peroxidases (GPx),
whichareantioxidantenzymesandprotectagainstoxidative
damage. Selenium is further involved in the alteration of
DNA methylation, blockage of the cell cycle, induction of
apoptosis, and inhibition of angiogenesis [13]. Selenium has
been associated with several cancers: it may protect against
prostate, lung, gastric, and colorectal cancer [10–12].
Moreover, we recently found evidence suggestive of an
inverse association with esophageal adenocarcinoma. This
associationwasfoundinwomen,neversmokers,andpersons
withalowintakeofantioxidants[14].Weidentiﬁedonlyone
study that looked into the association between selenium and
BE. That study found a lower average serum selenium con-
centration among patients with BE than among controls,
indicating a possible inverse association. Unfortunately, no
measure of relative risk or multivariable-adjusted results
werepresented.Twocross-sectionalstudiesamongBEcases
in the USA found indications for an inverse association
between serum selenium and markers of progression of BE
[15, 16]. Further, a recent study reported promotor hyper-
methylationofthegenecodingfortheselenoproteinGPx3in
Barrett’s esophagus tissue, thereby epigenetically inacti-
vating this gene [17]. We hypothesize that selenium status is
inversely associated with risk of BE, if selenium is involved
early in the process of carcinogenesis.
The selenium content of our food may vary considerably
between varieties of the same type of food, depending on
the soil where the food was grown [18]. For that reason,
selenium intake from diet cannot be estimated reliably
using questionnaires. Selenium status is therefore often
measured using biomarkers. In this study, we used toenails
as a biomarker of selenium intake. Toenails are a suitable
biomarker, because they reﬂect the intake of selenium for a
period up to 1 year [19, 20].
Within the prospective Netherlands Cohort Study on
diet and cancer, we investigated whether toenail selenium
levels were inversely associated with the risk of BE.
Materials and methods
Study design and participants
The prospective Netherlands Cohort Study on diet and
cancer was started in September 1986, when 58,279 Dutch
men and 62,573 women aged 55–69 were enrolled. The
subjects were selected at random from 204 Dutch muni-
cipal registries. All cohort members completed a self-
administered questionnaire and were requested to provide
toenail clippings at baseline. The study was described in
detail previously [21].
A case–cohort approach [22] was used for data pro-
cessing and analysis for efﬁciency; case subjects were
derived from the entire cohort, and the number of person-
years at risk for the entire cohort was estimated from a
subcohort of 3,500 subjects who were selected at random
from the full cohort at baseline.
The subcohort was followed-up for vital status and after
16.3 years (September 1986 to December 2002), only one
male subcohort member was lost to follow-up. We exclu-
ded subcohort members who reported having prevalent BE
or cancer (other than skin cancer) at baseline (Fig. 1).
The Medical Ethics Committee of Maastricht Univer-
sity, the Netherlands, has approved the study.
Follow-up for BE incidence
Incident BE cases in the total cohort were detected by
computerized record linkage to the nationwide network and
registry of histopathology and cytopathology in the Neth-
erlands (PALGA) [23]. This network was founded in 1971,
and an increasing number of laboratories joined PALGA
suchthatithasanationwidecoveragesince1991.Duetothis
incomplete coverage, we may have missed BE cases diag-
nosedbetweenbaseline(1986)and1991.Wecalculatedhow
many cases we may have missed by multiplying the mean
number of cases per year during the period a laboratory was
connected by the number of years the laboratory was not
connected to PALGA. This was done for each laboratory.
This way we calculated that we may have missed approxi-
mately 3% of BE cases. At each of the 64 pathology labo-
ratories in the Netherlands, excerpts of all pathology reports
are generated automatically. Each excerpt contains a so-
called PALGA diagnosis that describes topography, mor-
phology, function, procedure, and disease. These excerpts
are transferred to a central databank [23]. The linkage with
PALGAwascarriedoutfor16.3 yearsoffollow-up[24].All
links were then manually checked for false-positives.
Thereafter, one pathologist (A.L.C.D.) and one patholo-
gist in training (C.J.R.H.), who were blinded to the exposure
status (i.e., the selenium status) of the cases, reviewed the
excerpts of all pathology records to extract information on
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123theinitialdateofdiagnosisofBE,thetypeofmetaplasia,and
the degree of dysplasia. Excluded were BE cases with an
uncertaindiagnosis,oradiagnosisspecifyingthepresenceof
only non-intestinal-type metaplasia. Also excluded were
caseswith adiagnosisofesophagealorgastriccancer before
orlessthanahalfyearafterthediagnosisofBE,andBEcases
that were prevalent at baseline (Fig. 1).
Two deﬁnitions of BE were used: our primary case deﬁ-
nition included only subjects with esophageal SIM. The
secondary case deﬁnition included subjects (a) fulﬁlling the
primarycase deﬁnition or (b)with a pathologyreport stating
‘Barrett’s’, without a description of the type of metaplasia.
Furthermore,BEcasesmayprogresstohigh-gradedysplasia
or esophageal adenocarcinoma. We followed the BE cases
until December 31, 2002 and we identiﬁed the subgroup of
BE cases who showed one of these complications. For
analyses of BE cases who progressed to esophageal adeno-
carcinoma, we selected only BE cases in whom the adeno-
carcinoma was diagnosed more than a half year after the
diagnosis of BE. This time lag was chosen to be more sure
thatthiswas anew diagnosisof cancer that followed the BE.
Exposure data
In our cohort, about 75% of the subjects provided toenail
clippings. Toenail selenium determinations were carried
out by the Reactor Institute Delft (Delft University of
Technology, Delft, the Netherlands). The determination
was based on instrumental neutron activation analysis of
the 77mSe isotope (half-life 17.5 s). Each sample went
through 6 cycles of 17-s irradiation at a thermal neutron
ﬂux of 3 9 10
16 m
-2s
-1, 3-s decay, and 17-s counting at
1 cm from a 40% germanium detector. This method, its
accuracy and precision, and the use in the Netherlands
Cohort Study have been described in more detail previ-
ously [25–28].
In 1992, the toenail selenium determinations for the
subcohort members were carried out (for the purpose of
analysis of the association between selenium and risk of
several cancers). In 2008, the toenail selenium determina-
tions were carried out for the BE cases. In 1992, the ‘SBP’
facility was used for instrumental neutron activation anal-
ysis, and since 1996, the ‘CAFIA’ facility has been used.
To assess the comparability of these two methods, the
toenail selenium levels for 40 subcohort members were
assessed in 1996 with the ‘CAFIA’ facility in addition to
the original assessment with the ‘SBP’ facility [25]. The
mean (SD) selenium level assessed by the ‘CAFIA’ facility
[0.552 (0.05) lg/g] was comparable with mean selenium
levels assessed by the ‘SBP’ facility [0.551 (0.04) lg/g] for
these subjects. The Pearson correlation coefﬁcient between
toenail selenium levels assessed by the ‘CAFIA’ facility
Subcohort randomly 
drawn from total cohort
3,500
3,342                                                   
subcohort members
456 Barrett's esophagus 
cases with specialized 
intestinal metaplasia
626 Barrett's esophagus cases with 
specialized intestinal metaplasia or 
unknown metaplasia
2,423 285 397
2,294 285 397
2,039 253 346
Netherlands Cohort Study on diet and cancer (58,279 men and 62,573 women)
Exclusion if incomplete or inconsistent dietary data 
a
Exclusion if missing data on confounders
       Exclusion if toenail clippings were not provided, <10 mg of toenail clippings were available 
for selenium determination, or if problems occurred with selenium determination
792 cases
Exclusion of cases with esophageal or gastric cancer before or <½ 
year after Barrett's diagnosis, and cases with only non-intestinal 
metaplasia
Record linkage with PALGA until 31-12-2002
Exclusion of false-positive links
2,376 reports from 1,185 cases
Exclusion of prevalent cancer and Barrett's esophagus cases at baseline
Review by pathologist: exclusion of uncertain diagnoses
1,954 reports from 974 cases
868 cases
Fig. 1 Flow diagram of
subcohort members and
Barrett’s esophagus cases on
whom the analyses were based.
a For reasons of efﬁciency,
toenail material of Barrett’s
esophagus cases were not sent
to laboratory for instrumental
neutron activation analysis for
the determination of selenium
levels, if they had incomplete or
inconsistent questionnaire data.
Therefore, this exclusion
criterion did not anymore lead
to exclusion of cases at this
stage
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123and that estimated by the ‘SBP’ facility was 0.95
(p\0.01) [25]. It was concluded that both methods were
comparable.
In 1992, all toenail clippings provided were sent to the
Reactor Institute Delft for selenium determination. This
determination, however, yields unreliable results if the
nails weigh \10 mg and these measurements were thus
excluded. In 2007, we discovered that toenail clippings can
also be used as a source of DNA [29]. We therefore sep-
arated and saved 10–20 mg of toenail clippings from the
BE cases. If afterward more than 10 mg of toenail clip-
pings were left, we sent them to the Reactor Institute Delft
for selenium determination. In case there were problems
with the determination of toenail selenium, the subject was
excluded (Fig. 1).
The self-administered questionnaire, which was ﬁlled
out by all cohort members at baseline, consisted of a 150-
item food frequency questionnaire (FFQ) and other ques-
tions, e.g., on smoking, education, height, weight, and use
of medication. The FFQ asked about habitual consumption
in the year before the start of the study. We calculated
mean daily nutrient intakes using the Dutch food-compo-
sition table [30]. The questionnaire data were key entered
and processed in a standardized manner, blinded with
respect to cases/subcohort status to minimize observer bias
in coding and interpretation of the data.
Statistical analysis
To evaluate the potential inﬂuence of prediagnostic BE at
baseline on toenail selenium levels, cases were categorized
according to the year of follow-up in which they were
diagnosed. The mean toenail selenium levels of the cases
according to the year of follow-up were compared, and
differences were tested using a t-test. For the t-test, sele-
nium levels were ln-transformed to normalize the distri-
bution. For the case–cohort analysis, toenail selenium
levels were categorized into quartiles according to the
distribution in the subcohort. For continuous analysis, a
0.06 lg/g increment in toenail selenium was chosen. This
is equal to the average size of the two central quartiles.
We excluded subjects who had inconsistent or incom-
plete dietary questionnaire data, because dietary data were
needed as potential confounders and in subgroup analyses
[31]. Subjects with missing data on the confounders were
also excluded (Fig. 1).
The following variables were considered confounders
and included in the multivariable regression model: age,
sex, cigarette smoking (current yes/no, number of ciga-
rettes/day, and number of smoking years), alcohol con-
sumption (g/day), and body mass index (kg/m
2). The
following variables were considered potential confounders,
but were not included in the models because they did not
change the incidence rate ratio (RR) by[5%: highest level
of education, family history of esophageal or gastric can-
cer, reported long-term ([0.5 years) use of non-steroidal
anti-inﬂammatory drugs or aspirin, or lower esophageal
sphincter-relaxing medication [32], non-occupational
physical activity, daily intakes of the antioxidants vitamin
C, vitamin E, a-carotene, b-carotene, b-cryptoxanthin,
lycopene, and lutein/zeaxanthin. Figure 1 shows that
complete data were available for 2,039 subcohort mem-
bers, 253 BE cases fulﬁlling the primary case deﬁnition,
and 346 BE cases fulﬁlling the secondary case deﬁnition.
Multivariable-adjusted RR and corresponding 95%
conﬁdence intervals (CI) were estimated using Cox pro-
portional hazards models [33] in Stata 9.2 (StataCorp,
College Station, Texas, USA). Standard errors were esti-
mated using the robust Huber–White sandwich estimator to
account for additional variance introduced by sampling
from the cohort. This method is equivalent to the variance–
covariance estimator by Barlow [34]. We tested the pro-
portional hazards assumption using the scaled Schoenfeld
residuals [35]. Tests for dose–response trends were asses-
sed by ﬁtting ordinal exposure variables as continuous
terms. Two-sided p values are reported throughout the
article. The signiﬁcance level a was set at 0.05.
We investigated possible interactions between toenail
selenium status and sex, cigarette smoking status, BMI, and
intakes of several antioxidants by estimating RR in strata of
these exposures. The p value for interaction was assessed
by including a cross-product term in the model. To eval-
uate potential differences in the association during early
and late follow-up, we stratiﬁed our analysis by follow-up
period. Finally, we analyzed the subgroup of BE cases that
progressed to high-grade dysplasia and/or esophageal
adenocarcinoma during follow-up until 2002, as this is the
group most relevant with respect to disease burden.
Because of the low number of cases in this subgroup
(n = 21), we used two instead of four exposure categories:
above and below the median selenium concentration.
Results
Descriptives
Table 1 shows the mean toenail selenium levels of BE
cases, stratiﬁed by 2-year follow-up periods in which they
were diagnosed. The toenail selenium levels in the ﬁrst two
follow-up years were lower than in later follow-up years,
and this difference was borderline statistically signiﬁcant
(p = 0.07) for BE cases with SIM. As this difference may
indicate an effect of prediagnostic disease on toenail
selenium levels, we decided to exclude the ﬁrst 2 years of
follow-up from the analysis to prevent bias.
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123Characteristics of the subcohort and BE cases are
described in Table 2. Subcohort members had a median
toenail selenium level of 0.553 lg/g, with lower levels in
men (median 0.539 lg/g) than in women (0.564 lg/g). The
median toenail selenium levels in the two BE case groups
were comparable (0.552 and 0.553 lg/g). With respect to
other characteristics, there were more men and former
smokers among the cases, when compared with the sub-
cohort. Furthermore, cases had somewhat lower intakes of
carotenoids and were more likely to be long-term users of
non-steroidal anti-inﬂammatory drugs/aspirin and lower
esophageal sphincter-relaxing medication.
Main analysis
Table 3 presents multivariable-adjusted RR of BE
according to toenail selenium levels. The RR of BE with
SIM was 1.06 (95% CI: 0.71, 1.57) for the highest versus
the lowest quartile of toenail selenium, and no dose–
response trend was observed (p trend = 0.99). Multivari-
able analyses stratiﬁed by sex showed some differences in
associations for men (RR quartile 4 vs. quartile 1 = 1.31,
95% CI: 0.78, 2.21) and women (RR quartile 4 vs. quartile
1 = 0.85, 95% CI: 0.46, 1.57), but the interaction between
toenail selenium and sex was not statistically signiﬁcant
(p interaction = 0.18). The results were all comparable to
the age- and sex-adjusted results (Table 3). When we used
the less stringent secondary case deﬁnition of BE, the
results were very similar to those based on the primary case
deﬁnition (Table 3).
Interaction and subgroup analyses
When analyses were performed in strata of smoking status,
body mass index, or daily intake of antioxidants, no sta-
tistically signiﬁcant or important differences in associa-
tions were observed between strata, and the RR were all
around unity. Again, results were similar for the two BE
case groups (see Supplemental Table 1). Analyses strati-
ﬁed by follow-up period (early vs. late follow-up) showed
no statistically signiﬁcant associations or dose–response
trends in either period (data not shown).
An inverse association was found between toenail
selenium and risk of BE that progressed to high-grade
dysplasia and/or adenocarcinoma (Table 4). The multi-
variable RR for a toenail selenium level above the median
vs. below the median was 0.64, although the conﬁdence
interval was relatively wide (95% CI: 0.24, 1.76), due to
the low case number in this analysis (n = 21).
Discussion
To our knowledge, this is the second investigation, and
ﬁrst cohort study, into the possible role of selenium in the
etiology of BE, a precursor lesion of esophageal
Table 1 Toenail selenium levels (lg/g) in Barrett’s esophagus cases according to sex and time between baseline and diagnosis; Netherlands
Cohort Study (1986–2002, n = 120,852)
Cases
a Barrett’s esophagus
SIM SIM or unknown metaplasia
No. cases Toenail selenium level (lg/g) No. cases Toenail selenium level (lg/g)
Mean SD P
b Mean SD P
b
All cases 285 0.563 0.097 397 0.562 0.112
Men 163 0.556 0.100 226 0.558 0.127
Women 122 0.571 0.093 171 0.568 0.087
Follow-up year in which case was diagnosed
0–2 5 0.488 0.047 0.07 10 0.536 0.099 0.39
[2–4 17 0.531 0.086 31 0.566 0.210
[4–6 17 0.540 0.087 28 0.553 0.091
[6–8 38 0.557 0.058 54 0.552 0.068
[8–10 50 0.573 0.113 71 0.565 0.102
[10–12 55 0.555 0.096 74 0.561 0.120
[12–14 54 0.585 0.107 69 0.572 0.103
[14–17 49 0.568 0.099 60 0.565 0.094
a Mean (SD) selenium levels in subcohort members were 0.547 (0.126) lg/g for men (n = 1212) and 0.575 (0.109) lg/g for women (n = 1244)
b T test of mean toenail selenium levels (ln-transformed) for cases diagnosed in the ﬁrst 2 years of follow-up versus levels for cases diagnosed
during the remainder of follow-up years
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123adenocarcinoma. The results from this prospective cohort
study do not support our hypothesis that an inverse asso-
ciation might exist. Neither did we ﬁnd evidence of an
association in subgroups deﬁned by sex, smoking status,
BMI, intake of antioxidants or follow-up period.
TheDutchpopulationthatwasusedinthisstudyhasalow
to moderate toenail selenium level (mean: 0.564 lg/g in the
subcohort) when compared with mean levels found in other
populations (general population or control subjects): China
(Sichuan province) 0.211 lg/g [36], Finland 0.47 lg/g [37],
USA 0.83–0.92 lg/g [38], Colombia 0.945 lg/g [39], and
USA (South Dakota/Wyoming) 1.517 lg/g [19].
In the Netherlands, both the US and UK case deﬁnitions
of BE may have been used. The use of these deﬁnitions
Table 2 Characteristics of cases and subcohort members in the Netherlands Cohort Study (1986–2002, n = 120,852)
Characteristic Subcohort Barrett’s esophagus cases
(n = 2039)
a SIM (n = 253)
a SIM or unknown
metaplasia (n = 346)
a
Median (IQR) Median (IQR) Median (IQR)
Toenail selenium level (lg/g)
Total 0.553 (0.498–0.613) 0.552 (0.501–0.615) 0.553 (0.500–0.607)
Men 0.539 (0.483–0.602) 0.551 (0.495–0.615) 0.544 (0.492–0.605)
Women 0.564 (0.514–0.623) 0.555 (0.508–0.622) 0.565 (0.509–0.613)
Mean (SD)
b Mean (SD)
b Mean (SD)
b
Age at baseline (years) 61.2 (4.2) 60.8 (4.2) 61.1 (4.1)
Men (%) 49 59 58
Cigarette smoking status
Never smoker (%) 38 30 31
Former smoker (%) 37 51 48
Current smoker (%) 25 19 21
Ever cigarette smokers
Frequency of cigarette smoking (n/day) 15.2 (10.3) 16.6 (11.6) 16.5 (11.1)
Duration of cigarette smoking (years) 31.0 (12.2) 30.4 (11.8) 30.7 (12.0)
Ethanol intake (g/day) 10.2 (14.3) 10.8 (15.0) 10.8 (15.0)
Body mass index (kg/m
2) 25.0 (3.1) 25.3 (2.9) 25.3 (2.8)
Non-occupational physical activity (min/day) 73 (58) 69 (53) 70 (55)
Highest level of education
Primary (%) 27 27 30
Lower vocational (%) 22 20 20
Secondary and medium vocational (%) 37 36 35
University and higher vocational (%) 14 17 15
Vitamin C intake (mg/day) 104 (42) 101 (44) 100 (43)
Vitamin E intake (mg/day) 14 (6) 14 (6) 13 (6)
a-carotene intake (lg/day) 711 (588) 670 (502) 670 (512)
b-carotene intake (lg/day) 3,001 (1,589) 2,821 (1,382) 2,805 (1,398)
b-cryptoxanthin intake (lg/day) 181 (165) 177 (167) 176 (166)
Lycopene intake (lg/day) 1,214 (1,773) 1,203 (2,469) 1,125 (2,202)
Lutein/zeaxanthin intake (lg/day) 2,518 (1,079) 2,353 (904) 2,341 (925)
Family history of esophageal or gastric cancer (%) 8 8 8
Use of non-steroidal anti-inﬂammatory drugs and aspirin (%)
c 71 1 1 0
Use of lower esophageal sphincter-relaxing medication (%)
c 14 19 20
a Presented are the number of subcohort members or cases with complete data on toenail selenium level, age, sex, cigarette smoking (current yes/
no, number of cigarettes smoked daily, number of smoking years), alcohol consumption, and body mass index. Subcohort members and cases
with incomplete or inconsistent questionnaire data are excluded
b For categorical variables, a percentage is presented
c Self-reported use during more than 0.5 year
IQR interquartile range
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123may have changed over time, and different pathologists
may have used different deﬁnitions.
The ﬁrst strength of our study is its prospective character,
whichbringstheadvantageofmeasuringtheseleniumstatus
before the diagnosis of BE. This method makes it unlikely
that the exposure was changed due to the disease or knowl-
edge of the diagnosis and therefore it lowers the chance of
reversedcausation.Asecondstrengthisthesizeofthestudy.
This study had 80% power to detect an RR of 0.63 for all BE
casesandanRRof0.59forBEcaseswithSIM[40].Thirdly,
we had the possibility to adjust for confounding by several
lifestyle factors. A fourth strength is the use of toenail clip-
pings for the measurement of selenium exposure, because
selenium levels in clippings from all toes represent an
exposure period of up to 1 year. Measuring long-term
exposure is important as it more likely represents the expo-
sure in the etiologically relevant time window compared
with a measure of short-term exposure.
A limitation of our study is the lack of information about
gastroesophageal reﬂux disease and medications related to
Table 3 Incidence rate ratios of Barrett’s esophagus according to toenail selenium levels; Netherlands Cohort Study (1986–2002, n = 120,852)
Median
(lg/g)
Subcohort Barrett’s esophagus
SIM SIM or unknown metaplasia
Person time
at risk (years)
No. cases Age- and sex-
adjusted
Multivariable-
adjusted
a
No. cases Age- and sex-
adjusted
Multivariable-
adjusted
a
RR 95% CI RR 95% CI RR 95% CI RR 95% CI
All subjects
Quartiles of toenail selenium (boundaries in lg/g)
1( B0.498) 0.458 6,170 59 1 Reference 1 Reference 83 1 Reference 1 Reference
2( B0.552) 0.525 6,548 69 1.15 0.79 1.67 1.08 0.74 1.58 90 1.06 0.77 1.48 1.02 0.73 1.42
3( B0.613) 0.580 6,659 59 0.99 0.67 1.45 0.92 0.62 1.37 89 1.06 0.76 1.47 1.01 0.73 1.42
4( [0.613) 0.667 6,527 66 1.15 0.78 1.68 1.06 0.71 1.57 84 1.03 0.74 1.44 0.98 0.69 1.39
p trend
b 0.69 0.99 0.87 0.90
Continuous (0.06 lg/g
increment)
c
25,903 253 1.01 0.96 1.07 1.00 0.94 1.06 346 1.01 0.96 1.07 1.01 0.95 1.07
p interaction
d 0.17 p interaction 0.18 p interaction 0.06 p interaction 0.06
Men
Quartiles of toenail selenium (boundaries in lg/g)
1( B0.498) 0.458 3,658 39 1 Reference 1 Reference 55 1 Reference 1 Reference
2( B0.552) 0.525 3,078 37 1.10 0.68 1.79 1.06 0.64 1.76 54 1.14 0.75 1.73 1.10 0.72 1.70
3( B0.613) 0.580 2,830 34 1.10 0.67 1.80 1.07 0.64 1.78 44 1.02 0.66 1.57 0.99 0.63 1.55
4( [0.613) 0.667 2,596 38 1.35 0.84 2.19 1.31 0.78 2.21 48 1.21 0.79 1.86 1.18 0.74 1.87
p trend 0.26 0.33 0.50 0.61
Continuous (0.06 lg/g
increment)
12,162 148 1.03 0.98 1.09 1.03 0.97 1.09 201 1.04 0.98 1.09 1.03 0.98 1.09
Women
Quartiles of toenail selenium (boundaries in lg/g)
1( B0.498) 0.458 2,512 20 1 Reference 1 Reference 28 1 Reference 1 Reference
2( B0.552) 0.525 3,469 32 1.16 0.64 2.09 1.14 0.63 2.08 36 0.93 0.55 1.58 0.93 0.54 1.58
3( B0.613) 0.580 3,829 25 0.82 0.44 1.51 0.77 0.41 1.43 45 1.05 0.63 1.75 1.01 0.61 1.68
4( [0.613) 0.667 3,931 28 0.89 0.49 1.63 0.85 0.46 1.57 36 0.82 0.48 1.39 0.81 0.47 1.37
p trend 0.42 0.33 0.55 0.49
Continuous (0.06 lg/g
increment)
13,742 105 0.95 0.85 1.06 0.94 0.84 1.05 145 0.94 0.86 1.03 0.93 0.85 1.02
a adjusted for age (years), sex, cigarette smoking (current smoking status (yes/no), frequency (number of cigarettes/day), and duration (years)),
alcohol consumption (g/day), body mass index (kg/m
2)
b tests for dose–response trends were assessed by ﬁtting ordinal variables as continuous terms in the Cox proportional hazard model
c The 0.06 lg/g increment for continuous analyses is equal to the average size of the two central quartiles
d p-value for interaction between sex and toenail selenium level, based on cross-product term in the Cox proportional hazard model
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123this disease. In the baseline questionnaire, one question
concerned the long-term use of medications and the disease
for which these were prescribed. However, we believe that
the reported use of reﬂux medication and antacids, and the
presence of gastroesophageal reﬂux disease were substan-
tially lower than the actual frequency. This prohibited us to
use this information in the analysis. Consequently, we were
not able to evaluate if gastroesophageal reﬂux disease is a
confounder or intermediate factor in the relation between
selenium and BE. We therefore suggest that this study is
replicated in a population for which information on gas-
troesophageal reﬂux is available, to evaluate its possible
role as confounder or intermediate factor. A second limi-
tation is the single measurement of the exposure. Selenium
exposure may have changed during follow-up due to
changed selenium levels in foods or changed dietary habits.
Third, we did not have the opportunity to verify the
absence of BE in the subcohort members who were not
diagnosed with BE. BE usually occurs in patients with
gastroesophageal reﬂux disease, but it has also been
described in asymptomatic individuals, who are therefore
not diagnosed with the disease. Three studies investigated
the prevalence of BE among asymptomatic individuals in
the USA and reported prevalences ranging from 1 to 25%
[41–43]. However, in our cohort study, any undiagnosed
BE cases would most likely not have inﬂuenced the RR.
This is because the imperfect sensitivity (i.e., false-nega-
tives) is combined with good speciﬁcity (i.e., few false-
positives), and the chance of diagnosis is likely indepen-
dent of selenium status. The misclassiﬁcation of the disease
status then is non-differential and will not inﬂuence the RR
[44]. Still, a consequence of undiagnosed cases is a reduced
power to detect an existing association. A fourth limitation,
related to the third, is caused by the incomplete coverage of
the Netherlands by PALGA before 1991. There may have
been some BE cases that were diagnosed in laboratories
when these had not yet joined PALGA. If these cases were
not followed-up, we missed their diagnosis. If they were
followed-up after the laboratory joined PALGA, the inci-
dence date we registered is more recent than the true
incidence date. We assessed that we may have missed 3%
of the BE cases in our cohort at most.
If in line with our null ﬁndings, there is truly no asso-
ciation between toenail selenium and the risk of BE, this
does not preclude a possible association between selenium
and progression of BE to high-grade dysplasia or adeno-
carcinoma. We observed an RR well below unity for sub-
jects with a toenail selenium level above the median in
those BE cases who progressed to high-grade dysplasia
and/or esophageal adenocarcinoma. This RR, however,
was based on few cases and was not statistically signiﬁcant.
In a previous analysis, we found indications for an inverse
association between selenium and risk of esophageal ade-
nocarcinoma in some subgroups: women, never smokers,
and low antioxidant consumers [14]. These above-men-
tioned observations are in agreement with observations by
two other studies that found indications for a role of sele-
nium in later stages of the carcinogenesis of esophageal
adenocarcinoma [15, 16]. Selenium might be an interesting
preventive agent for progression to esophageal adenocar-
cinoma in patients with BE, but this requires a larger body
of evidence.
In conclusion, no evidence of an inverse association
between toenail selenium and risk of BE was found in this
study. An inverse association might exist for BE cases that
progress to high-grade dysplasia and/or esophageal ade-
nocarcinoma, but results from other studies are needed
before any ﬁrm conclusions can be drawn. Preferably,
future studies should have a prospective character and
should have the possibility to investigate the role of gas-
troesophageal reﬂux in this association. Also, it would be
informative to study the relation between selenium and risk
Table 4 Incidence rate ratios of Barrett’s esophagus cases who developed high-grade dysplasia or adenocarcinoma according to toenail
selenium levels; Netherlands Cohort Study (1986–2002, n = 120,852)
Median within
category lg/g
Subcohort Barrett’s esophagus with high-grade dysplasia and/or adenocarcinoma
Age- and sex-adjusted Multivariable-adjusted
a
Person time
at risk (years)
No. cases RR 95% CI RR 95% CI
Categories of toenail selenium, based on a median split (boundary in lg/g)
1( B0.552) 0.497 12,717 13 1 Reference 1 Reference
2( [0.552) 0.615 13,185 8 0.63 0.26 1.56 0.64 0.24 1.76
Continuous (0.06 lg/g Increment)
b 25,903 21 1.10 0.99 1.22 1.11 0.99 1.24
a adjusted for age (years), sex, cigarette smoking (current smoking status (yes/no), frequency (number of cigarettes/day), and duration (years)),
alcohol consumption (g/day), and body mass index (kg/m
2)
b The RRs of the continuous analyses are inﬂuenced by one case with a very high toenail selenium level (1.612 lg/g). When this case was
excluded, the age- and sex-adjusted RR was 0.96 (95% CI 0.79–1.17) and the multivariable-adjusted RR was 0.96 (95% CI 0.77–1.20)
2266 Cancer Causes Control (2010) 21:2259–2268
123of BE in a population with selenium levels that are lower or
higher compared with our study population.
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